Key result
Statins significantly lower C-reactive protein levels in a non-dose-dependent manner, but do not affect fibrinogen levels or show clear effects on other nonlipid serum markers.
Why the study?
Do statins improve nonlipid serum markers associated with cardiovascular disease?
Population
Participants in studies evaluating the effect of statins on nonlipid serum markers
Design
Meta-analysis
Authors
Loading...
Statins lower CRP independently of dose without fibrinogen effects; confirms selective anti-inflammatory action and extends pleiotropic marker research.
Meta-Analysis
Do statins improve nonlipid serum markers associated with cardiovascular disease?
Statins significantly lower C-reactive protein levels independent of dose, suggesting an anti-inflammatory mechanism, though this reduction does not correlate with lipid lowering or cardiovascular outcomes.
Balk et al. (2003) conducted a meta-analysis in Cardiovascular Disease. Statins was evaluated on Nonlipid serum markers (including C-reactive protein and fibrinogen). Statins significantly lower C-reactive protein levels in a non-dose-dependent manner, but do not affect fibrinogen levels or show clear effects on other nonlipid serum markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: